In vivo effects of recombinant human erythropoietin on circulating human hemopoietic progenitor cells.
Recombinant human erythropoietin (rhEpo), now available, has become increasingly more important for clinical use, e.g., in the treatment of anemia of chronic renal failure, and has been shown to reverse anemia in these patients. When patients with anemia of chronic renal failure were treated with rhEpo at dosages between 40 and 120 U/kg three times per week, the numbers of circulating erythroid burst-forming units (BFU-E) and granulocyte-erythrocyte-macrophage-megakaryocyte colony-forming units (CFU-GEMM) significantly increased during the first week of therapy. In contrast, the incidence of circulating granulocyte-monocyte CFU (CFU-GM) was not significantly altered.
Ganser
A
A
Department of Hematology, University of Frankfurt, FRG.
Bergmann
M
M
Völkers
B
B
Grützmacher
P
P
Scigalla
P
P
Hoelzer
D
D
D002469:Cell Separation; D004921:Erythropoietin / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013234:Stem Cells / Q000187:drug effects
D011994:Recombinant Proteins; D004921:Erythropoietin